Vertex Pharmaceuticals continues to generate most of its revenue from its cystic fibrosis (CF) franchise. The company's ...

Vertex Pharmaceuticals (VRTX) has drawn attention with new data from its RUBY-3 trial, showing that povetacicept has achieved ...

Vertex Pharmaceuticals Incorporated (VRTX) is a leading U.S. biopharmaceutical company, headquartered in Boston, ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

The stock of niche financial software company Vertex ( VERX 4.13%) didn't get a very good start to the trading week at all. Its value fell by nearly 10% that day, due largely to a quarterly earnings ...

And I do have several favorite stocks that fit that description. My top growth stock to buy in November is one that I've ...

Shares of Vertex Pharmaceuticals Inc. VRTX shed 1.63% to $409.47 Friday, on what proved to be an all-around favorable trading ...

Vertex, Inc. (NASDAQ:VERX) experienced a price target cut on November 5, 2025, with Goldman Sachs lowering its target from ...

KING OF PRUSSIA, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results ...

Both companies are leaders in their niche with excellent growth prospects. They could deliver market-beating returns through ...